Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127486 · ClinicalTrials.gov registry record · Phase 4
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
A Phase 4 study of Migraine and Episodic Migraine, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 580
- Enrollment target
- 20
- Study locations
NCT05127486: Completed Phase 4 study of Migraine and Episodic Migraine, sponsored by Eli Lilly and Company.
NCT05127486 is a Phase 4 study of Migraine and Episodic Migraine that has completed, run by Eli Lilly and Company. The registered enrollment target is 580 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05127486, a Phase 4 study of Migraine and Episodic Migraine, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 580 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
Primary Outcome
A migraine headache day is a calendar day on which a migraine headache or probable migraine headache occurred. Overall mean percentage across months 1 through 3 of participants with at least a 50% reduction in monthly migraine headache days from baseline (50% response rate) using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly m
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimegepant
- DRUG Galcanezumab
Study Locations (20)
California
- Velocity Clinical Research, Banning - Banning
- Velocity Clinical Research, Chula Vista - Chula Vista
- Wr- Pri, Llc - Encino
- Velocity Clinical Research, San Diego - La Mesa
- California Medical Clinic for Headache and The Los Angeles Headache Center (Research Facility) - Los Angeles
- Pharmacology Research Institute - Newport Beach
- Velocity Clinical Research, North Hollywood - North Hollywood
- Anderson Clinical Research - Redlands
- Center for Clinical Trials of Sacramento - Sacramento
- Velocity Clinical Research, Huntington Park - Santa Ana
- Encompass Clinical Research - Spring Valley
Florida
- Innovative Research of West Florida - Clearwater
- AMR Miami - Coral Gables
- Accel Research Sites- Clinical Research Unit - DeLand
- Velocity Clinical Research, Hallandale Beach - Hallandale
- Accel Research Sites-LKD CRU - Lakeland
Arizona
- Gilbert Neurology - Gilbert
- Foothills Research Center / CCT Research - Phoenix
- Alliance for Multispecialty Research, LLC Tempe - Tempe
Connecticut
- CMR of Greater New Haven, LLC - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 4 |
What the finished NCT05127486 record still lists
NCT05127486 is an interventional study that assigns participants to a tested intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (64% higher).
The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05127486 names 20 study sites across 4 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05127486 about?
NCT05127486 is a clinical study titled "A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine". The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
What is the current status of trial NCT05127486?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 580 participants. The study started on 2021-12-06. Estimated completion is 2023-05-23.
What conditions does trial NCT05127486 study?
This clinical trial studies the following conditions: Migraine, Episodic Migraine.
What interventions are being tested in trial NCT05127486?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG), Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT05127486?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05127486 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05127486's enrollment target sits among peer trials
580 18th of 102 higher than 85 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI